Corona Remedies to host JP Morgan-led analyst meet on Sep 23
- Corona Remedies to hold analyst meet on Sep 23, 2026
- Session organized by JP Morgan in Ahmedabad at 2:00 pm
- Discussions limited to publicly available information
- No unpublished price-sensitive information to be shared

*this image is generated using AI for illustrative purposes only.
Corona Remedies will host a group meeting with analysts and investors on September 23, 2026. The session is scheduled for 2:00 pm in Ahmedabad and will be organized by JP Morgan.
The company disclosed the schedule pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Meeting Details
The interaction will focus on publicly available information. The company stated that no unpublished price-sensitive information (UPSI) is intended to be discussed during the event.
| Day, Date & Time | Organized By | Nature of Meeting | Place |
|---|---|---|---|
| Wednesday, September 23, 2026, 2:00 pm | JP Morgan | Group Meeting | Ahmedabad |
Chetna Dharajiya, Company Secretary and Compliance Officer, signed the intimation filed with the Bombay Stock Exchange and the National Stock Exchange of India Limited. The notice was issued on September 18, 2026.
The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company. The intimation is also available on the company's website.
Historical Stock Returns for Corona Remedies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.48% | +0.05% | +4.20% | +41.05% | +53.07% | +53.07% |
What specific operational or financial metrics is JP Morgan likely to prioritize in their analysis of Corona Remedies during this group meeting?
How might the market react to Corona Remedies' stock price if no new strategic initiatives are disclosed during this compliance-driven session?
Are there any upcoming regulatory changes in India's pharmaceutical sector that could influence the agenda of this September 2026 investor interaction?


































